Third International Stroke Trial "IST-3"

Completed

Phase 3 Results

Eligibility Criteria

Inclusion Criteria

Patients with symptomatic, CT- or MRI-verified acute ischemic stroke who are able to be treated within 6 hours of stroke onset. For any patient being considered for the trial, there should be no clear indication for, or clear contraindication to, thrombolytic therapy with intravenous rt-PA, and the responsible physician should consider the treatment 'promising but unproven' for that patient.

Exclusion Criteria

Females who are pregnant, breastfeeding, or of childbearing potential, and persons who have had major surgery, traumatic injury, gastrointestinal or urinary tract hemorrhage within the past 21 days, who have had arterial puncture at a non-compressible site within the past 7 days, who receive oral or intravenous anticoagulant therapy that results in an activated partial thromboplastin time (aPTT) or international normalized ratio (INR) outside of the normal range for untreated patients, who have a known platelet defect or clotting abnormality, who have hypo- or hyper-glycemia severe enough to cause neurological symptoms, or who have a comorbid illness likely to cause death within a few months, will be excluded from this study.